In a report released on May 10, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $21.75.
According to TipRanks, Canino is a 4-star analyst with an average return of 5.5% and a 47.15% success rate. Canino covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Blueprint Medicines, and Arvinas Holding Company.
In addition to Stifel Nicolaus, Syndax Pharmaceuticals also received a Buy from Barclays’s Peter Lawson in a report issued on May 9. However, on the same day, Scotiabank reiterated a Hold rating on Syndax Pharmaceuticals (NASDAQ: SNDX).
Based on Syndax Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $72.47 million. In comparison, last year the company had a GAAP net loss of $39.19 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syndax Pharmaceuticals (SNDX) Company Description:
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Read More on SNDX:
